TABLE 1.
Antiviral activity spectrum of LabyA1 and LabyA2
| Virus | Tested cells | Assay | IC50 (μM) |
CC50 (μM) |
||
|---|---|---|---|---|---|---|
| LabyA1 | LabyA2 | LabyA1 | LabyA2 | |||
| Enveloped viruses | ||||||
| CHIKV | 293-T | Quantification of cells infected with 3′-GFP-CHIKV | 2.2 | NDb | ND | ND |
| CHIKV (pseudotype) | 293-T | Quantification of lentiviral luciferase reporter particles pseudotyped with CHIKV glycoproteins | 1.8 | >5.0 | ND | ND |
| DENV-1 | MDDC | Determination of infected cells by flow cytometry (E protein immunostaining) | 0.8 | 12.0 | >24.1 | >26.0 |
| DENV-2 | Huh-7 | Determination of infected cells by high content imaging (E-protein immunostaining) | 1.8 | 8.0 | >24.1 | >26.0 |
| DENV-2 | Huh-7 | Quantification of viral load in cell culture supernatant by qRT-PCR | 2.0 | 7.6 | >24.1 | >26.0 |
| DENV-2 | MDDC | Determination of infected cells by flow cytometry (E protein immunostaining) | 0.4 | 5.2 | >24.1 | >26.0 |
| DENV-2 | MDDC | Quantification of viral load in cell culture supernatant by qRT-PCR | 0.3 | 4.2 | >24.1 | >26.0 |
| DENV-3 | MDDC | Determination of infected cells by flow cytometry (E protein immunostaining) | 1.1 | 9.4 | >24.1 | >26.0 |
| DENV-4 | MDDC | Determination of infected cells by flow cytometry (E protein immunostaining) | 0.3 | 4.0 | >24.1 | >26.0 |
| HCMV | NHDF | Quantification of virus-derived GFP expression in infected cells | 1.3 | 5.4 | ND | ND |
| HCV | Huh-7 | Intracellular Renilla luciferase activity of HCV JcR2a reporter construct | 1.1 | 1.7 | >50.0 | >50.0 |
| HIV (laboratory strains)a | MT-4 T cells | Determination of virus-induced cytopathicity | 1.9 | ND | 33.0 | ND |
| PBMC | Quantification of viral load via p24-Ag ELISA | 1.7 | ND | 45.0 | ND | |
| MDM | Quantification of viral load via p24-Ag ELISA | 2.4 | ND | ND | ND | |
| HIV (clinical isolates)a | PBMC | Quantification of viral load via p24-Ag ELISA | 1.0 | ND | 45.0 | ND |
| HSV-1a | HEL | Determination of virus-induced cytopathicity | 1.6 | 12.4 | >48.2 | ND |
| HSV-1 (Tk deficient)a | HEL | Determination of virus-induced cytopathicity | 1.9 | 10.7 | >48.2 | ND |
| HSV-2a | HEL | Determination of virus-induced cytopathicity | 0.4 | 5.5 | >48.2 | ND |
| HSV-2 (Tk deficient)a | HEL | Determination of virus-induced cytopathicity | 0.3 | 3.2 | >48.2 | ND |
| KSHV | HEK-293 (GFP) | Determination of virus-induced cytopathicity by counting remaining GFP fluorescent cells | 2.0 | 15.0 | ND | ND |
| TBEV | Vero | Visual plaque reduction after cells were immunostained for viral E protein | 24.1 | >26.0 | >24.1 | >26.0 |
| WNV | Huh-7 | Quantification of viral load in cell culture supernatant by microplaque assay | 0.2 | 0.7 | >48.2 | >52.0 |
| ZIKV-976 | Huh-7 | Determination of infected cells by high-content imaging (E protein immunostaining) | 2.0 | 9.6 | >24.1 | >26.0 |
| ZIKV-976 | Huh-7 | Quantification of viral load in cell culture supernatant by qRT-PCR | 1.8 | 5.7 | >24.1 | >26.0 |
| ZIKV-H/PF-2013 | Huh-7 | Determination of infected cells by high-content imaging (E protein immunostaining) | 1.6 | 3.3 | >24.1 | >26.0 |
| ZIKV-H/PF-2013 | Huh-7 | Quantification of viral load in cell culture supernatant by qRT-PCR | 1.6 | 3.4 | >24.1 | >26.0 |
| Nonenveloped viruses | ||||||
| Adenovirus 5 | A-549 | Determination of virus-induced cytopathicity by MTT assay | >25.0 | >50.0 | ND | ND |
| CSV B | Vero | Determination of virus-induced cytopathicity by MTT assay | >48.2 | >52.0 | ND | ND |
a
IC50 values and CC50 (cellular cytotoxicity) values for HIV, HSV-1, and HSV-2 are taken from reference 16.
b
ND, not determined.